Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Rallybio Corporation - Common Stock
(NQ:
RLYB
)
0.6492
+0.0136 (+2.14%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 25, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Rallybio Corporation - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
RALLYBIO CORP (NASDAQ:RLYB) Reports Q3 2025 Earnings Beat Fueled by Asset Sale and Advances Clinical Pipeline
↗
November 06, 2025
Rallybio posts Q3 profit on one-time gain, extends cash runway to 2027, and advances its C5 inhibitor clinical pipeline.
Via
Chartmill
Topics
Earnings
Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates
November 06, 2025
From
Rallybio Corporation
Via
Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
October 23, 2025
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
October 16, 2025
Via
Benzinga
Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
September 25, 2025
From
Rallybio Corporation
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
September 23, 2025
Via
Benzinga
Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program
September 03, 2025
From
Rallybio Corporation
Via
Business Wire
Avant Technologies and Ainnova Tech Announce Enhanced Patient Recruitment Strategy Ahead of FDA Clinical Trial
August 12, 2025
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:RLYB),(NASDAQ:BTAI),(NYSE:PFE) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates
August 07, 2025
From
Rallybio Corporation
Via
Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
↗
July 14, 2025
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
July 09, 2025
Via
Benzinga
Top movers in Tuesday's session
↗
July 08, 2025
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top gainers and losers in today's session.
Via
Chartmill
Most active stocks in Tuesday's session
↗
July 08, 2025
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the most active stocks in today's session.
Via
Chartmill
Here's Why Shares in Recursion Pharmaceuticals Surged Today
↗
July 08, 2025
Via
The Motley Fool
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
July 08, 2025
Via
Benzinga
What's going on in today's session
↗
July 08, 2025
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Via
Chartmill
Gapping stocks in Tuesday's session
↗
July 08, 2025
In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down.
Via
Chartmill
Why Is Microcap Rallybio Stock Trading Higher On Tuesday?
↗
July 08, 2025
Rallybio sells its stake in preclinical HPP drug REV102 to Recursion in a deal worth up to $25 million, including equity and milestone payments.
Via
Benzinga
Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals
July 08, 2025
From
Rallybio Corporation
Via
Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
↗
June 30, 2025
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
↗
June 13, 2025
Via
Benzinga
Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
June 12, 2025
From
Rallybio Corporation
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
June 04, 2025
Via
Benzinga
Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates
May 08, 2025
From
Rallybio Corporation
Via
Business Wire
Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference
April 29, 2025
From
Rallybio Corporation
Via
Business Wire
This General Motors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
↗
April 15, 2025
Via
Benzinga
Which stocks have an unusual volume on Monday?
↗
April 14, 2025
Unusual volume stocks are being observed in Monday's session.
Via
Chartmill
This PTC Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
↗
April 09, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
April 08, 2025
Via
Benzinga
Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints
↗
April 08, 2025
Rallybio ends RLYB212 trial for FNAIT; shifts focus to RLYB116 and preclinical assets with 2025 trial milestones and $6 billion market potential.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today